Boston Scientific and Blackstone Commit $455M to Heart Pump Development
Blackstone Life Sciences and Boston Scientific signed a $455 million deal to co-fund the VITALYST temporary heart pump for patients with cardiogenic shock.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Boston Scientific and Blackstone Life Sciences have announced a $455 million collaboration. The companies will jointly fund development of VITALYST, a temporary heart pump designed to treat cardiogenic shock, a medical emergency in which the heart cannot pump enough blood.
According to TradingView, this is the first time the two companies have pooled funds to develop a Boston Scientific product. The release does not disclose clinical results, regulatory status, a cost breakdown or funding milestones. Dow Jones Newswires, citing Blackstone, quotes Nicholas Galakatos, head of Blackstone Life Sciences: "We believe the Vitalyst system has the potential to improve on the efficacy and safety of currently available mechanical circulatory support technologies."
why it matters
For markets, the deal matters mainly to Boston Scientific and the medical technology sector. External funding can ease some early-stage development costs, but launch timing and clinical data have not been disclosed, so its effect on the company's financial results is hard to gauge.
market impact
Boston Scientific shares: outside funding eases development spending, with a moderate effect
tags
instruments
sources
- Boston Scientific (BSX) Enters $455M Heart Pump Development Deal — TradingView, 2 November 2026 at 22:54 UTC
- Blackstone, Boston Scientific Sign $455M Deal to Co-Fund Heart Pump — Dow Jones Newswires, 2 November 2026 at 23:14 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗